Research programme: inhaled muscarinic M3 receptor antagonists - Pfizer

Drug Profile

Research programme: inhaled muscarinic M3 receptor antagonists - Pfizer

Alternative Names: PF-4522971

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in United Kingdom (Inhalation, Inhalant)
  • 22 Sep 2010 Preclinical trials in Chronic obstructive pulmonary disease in United Kingdom (Inhalation)
  • 22 Sep 2010 Pharmacodynamics data from an In vitro trial presented at the 20th Annual Congress of the European Respiratory Society (ERS-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top